Síndrome de encefalopatía posterior reversible asociado a quimioterapia. Gemcitabina como agente causal

Sánchez-Cendra, Cristina; Malón-Giménez, Diego; Guerra-Martínez, Juan A; Calzas-Rodríguez, Julia; Antón-Pascual, Beatriz; Olmo-Sánchez, Aitor.
Rev. neurol. (Ed. impr.) ; 64(12): 574-575, 16 jun., 2017.
Artículo en Español | IBECS (España) | ID: ibc-164010

Documentos relacionados

  1. Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example.
  2. Regorafenib-induced hyperammonemic encephalopathy.
  3. Effects of taxane-induced peripheral neuropathy on hand dexterity impairment: evaluation of quantitative and subjective assessments.
  4. Psychological predictors of chemotherapy-induced nausea in women with breast cancer: Expectancies and perceived susceptibility.
  5. Evaluation of the CNC<sup>®</sup> prosthetic system in recurrent breast cancer patients with chemotherapy-induced alopecia: a pilot study.
  6. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
  7. Clinician and patient experiences when providing and receiving information and support for managing chemotherapy-induced peripheral neuropathy: A qualitative multiple methods study.
  8. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial.
  9. [Adverse effects of new breast cancer therapies : when to react ?]
  10. Oral Propolis, Nutritional Status and Quality of Life with Chemotherapy for Breast Cancer: A Randomized, Double-Blind Clinical Trial.